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Introduction: Human cytomegalovirus is a major cause of morbidity in kidney transplant
patients.
Objectives: We  aimed to study viral replication and serological response in the ﬁrst months
post  kidney transplant in patients undergoing universal prophylaxis or preemptive therapy
and correlate the ﬁndings with the clinical course of Human cytomegalovirus infection.
Patients and methods: Independent from the clinical strategy adopted for managing Human
cytomegalovirus infection, prophylaxis versus preemptive therapy, the pp65 antigenemia
assay and serological response were assessed on the day of transplantation, and then weekly
during the ﬁrst three months of post-transplant.
Results: From the 32 transplant recipients, 16 were positive for pp65 antigenemia, with a
similar incidence rate in each group. There were no positive results in the ﬁrst three weeks
of  monitoring; the positivity rate peaked at week eight. There was a trend for a higher and
earlier frequency of positivity in the universal prophylaxis group in which the course of the
Human cytomegalovirus infection was also more severe. Despite the differences in clinicalpicture and in the initial immunosuppressant schedule, the serological response was  similar
in  both groups.
onitoring during the ﬁrst three post-transplant months has a positiveConclusion: Routine mPlease cite this article in press as: Carvalho FR, et al. Clinical correlates of pp65 antigenemia monitoring in the ﬁrst months of post kidney
transplant in patients undergoing universal prophylaxis or preemptive therapy. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.09.016
impact on the early detection of Human cytomegalovirus viral replication allowing for timely
treatment in order to reduce morbidity of the disease. The strategy of universal therapy
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employing intravenous ganciclovir was associated to a worse clinical course of the Human
cytomegalovirus infection suggesting that the use of >10 cells/2 × 105 leukocytes as a cut-off
in  this setting may be inappropriate.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/Introduction
Human cytomegalovirus (HCMV), a DNA virus, member of her-
pesviridae family, is one of the major problems associated with
organ transplants, directly affecting clinical outcomes and
mortality.1–4 In this context, different strategies for monitor-
ing, prevention, and treatment have been applied.5 In several
centers, the HCMV screening and monitoring is generally per-
formed using assays for viral biomarkers identiﬁcation, such
as phosphoprotein 65 (pp65) or viral DNA by polymerase chain
reaction (PCR).6–8
In preemptive therapy, diagnostic tests are usually per-
formed weekly to guide therapeutic decisions, based on
previously deﬁned cut-off. In high risk patients, however,
universal prophylaxis has been used, with antiviral drugs
administered immediately after transplantation, usually for
at least three months.9,10
In transplant recipients undergoing universal prophylaxis
screening is not usually performed, and data on potential
early replication are unknown. However, it has been estab-
lished that late disease, following completion of treatment
with antiviral drugs, is more  likely to occur in this group.11,12
In view of that, some centers use monitoring strategy sim-
ilar to preemptive protocol after ending treatment.13,14 The
objective of the present study was to study viral replication
and serological response in the ﬁrst three months after kidney
transplantation in patients undergoing universal prophylaxis
or preemptive therapy and correlate the ﬁndings with the clin-
ical course of HCMV infection.
Patients  and  methods
Blood samples of patients undergoing kidney transplanta-
tion at the Nephrology Division of a University Hospital were
analyzed, from April 2014 (a time when pp65 assay was
implemented in our center) to September 2015. This was
an observational, prospective, longitudinal study, which ana-
lyzed the HCMV replication proﬁle by pp65 antigenemia assay,
with internal validation by qPCR assay. In addition, serum
levels of anti-HCMV immunoglobulins were quantiﬁed. Clin-
ical ﬁndings and other laboratory test results were obtained
from patients’ charts. The research protocol was approved by
the Research Ethics Committee of the Medical School (CAAE:
18768213.1.0000.5243).
Irrespective of the clinical strategy adopted, the monitor-Please cite this article in press as: Carvalho FR, et al. Clinical correlates 
transplant in patients undergoing universal prophylaxis or preemptive ther
ing consisted in detection of viral replication in neutrophils
infected by HCMV on the day of transplantation and weekly
during the ﬁrst three months. An additional evaluation was
conducted at the end of the sixth month post-transplantation.licenses/by-nc-nd/4.0/).
Patients were grouped according to the type of the strategy
adopted (preemptive therapy vs. prophylactic therapy).
The pp65 assay was performed by indirect immunoﬂuo-
rescence using BriteTM Turbo kit (IQ Products, Groningen,
Netherlands) following the manufacturer’s instructions.
Results were expressed as the number of positive cells per
2 × 105 leukocytes. Sample processing and analysis were per-
formed in a blinded fashion by the laboratory staff and the
reports were made available on the electronic chart system of
the hospital.
Quantiﬁcation of anti-CMV IgM and IgG was performed
using the commercial kits Architect CMV IgG Reagent and
Architect CMV  IgM Reagent, respectively (Abbott, Ireland),
using a HCMV lysate (strain AD169) in a chemiluminescent
microparticles immunoassay. The serum levels of anti-HCMV
immunoglobulins (IgM and IgG) was measured on the day of
transplantation and weekly during the ﬁrst three months. An
additional evaluation was conducted at the end of the sixth
month post-transplantation.
The type of strategy (preemptive or universal) was chosen
at the discretion of the medical assistants. In case of pre-
emptive therapy, intravenous ganciclovir was initiated when
at least 10 positive cells by 2 × 105 leukocytes (cut-off) were
identiﬁed in the pp65 assay. In prophylactic therapy, antiviral
treatment with ganciclovir was administered soon after trans-
plantation, and maintained for three consecutive months,
according to the following criteria: donor CMV  IgG positive
with CMV  IgG negative receptor; donor > 60 years; serum
creatinine of deceased donor >1.5 mg/dL; or whenever the
induction therapy was based on thymoglobulin.
Universal prophylaxis with intravenous ganciclovir
(5 mg/kg) was implemented according to previous institu-
tional protocol: P.O. 1 to P.O. 14, twice a day; P.O. 15 to P.O. 30,
three times a week; P.O. 31 to P.O. 60, twice a week, and P.O. 61
to P.O. 90, once a week. The dose of ganciclovir was adjusted
to the patient’s renal function.
The results were expressed as mean ± SD. Differences
between groups were analyzed by unpaired Student’s t test
or Mann–Whitney, according to the distribution pattern. Fre-
quencies were compared using Fisher’s exact test. p values
<0.05 were considered statistically signiﬁcant. Statistical anal-
ysis was performed using 5.0 GraphPad Prism program.
Results
Thirty-two successful kidney transplants were performed dur-of pp65 antigenemia monitoring in the ﬁrst months of post kidney
apy. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.09.016
ing the study period. Baseline characteristics of donors are
shown in Table 1. Their mean age was 44 ± 14 years. Intracra-
nial bleeding (41%) was the main cause of death, and all
were seropositive for HCMV. The mean cold ischemia time
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Table 1 – Baseline characteristics of kidney donors.
Donor parameters All Universal prophylaxis Preemptive therapy
N 32 18 14
Age (y) 44 ± 14 49 ± 12 49 ± 9
Male gender, f  (%) 17 (53%) 10 (56%) 7 (50%)
Skin color, f (%)
White 20 (63%) 10  (56%) 9  (64%)
Non-White 12 (37%) 8  (44%) 5 (36%)
Serum creatinine (mg/dL)
Female 0.86 ± 0.13 0.81±  0.09 1.00 ± 0.14
Male 1.00 ± 0.23 1.06 ± 0.27 0.97 ± 0.20
Cold ischemia time (h) 18.5 ± 8.5 19 ± 9.5 15 ± 5.5
Cause of brain death, f (%)
Intracranial bleeding 13 (41%) 9 (50%) 4 (29%)
Trauma 10 (31%) 5 (28%) 5 (36%)
Intracranial ischemia 6 (19%) 4 (22%) 2 (14%)
Other 3 (9%) – 3 (21%)
Serum anti-HCMV IgG 32 (100%) 18 (100%) 14 (100%)
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symptoms; therefore, it is a useful tool to promptly support
clinical decisions and has been considered the gold standard
for monitoring HCMV viral replication in solid organ trans-
plant recipients.9,16,17
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 8 9 10 11 12 24Mean ± SD. No statistically signiﬁcant was found for any of the param
as 18.5 ± 8.5 hours and there were no signiﬁcant differences
hen comparing the characteristics of donors whose organs
ere allocated to recipients undergoing universal prophylaxis
r preemptive therapy.
Out of 32 recipients (44% male, 50% white), 18 received
niversal prophylaxis and 14 preemptive therapy. Baseline
haracteristics of recipients are shown in Table 2. Again, no
tatistically signiﬁcant differences were found when compar-
ng baseline parameters between groups.
The pp65 antigenemia assay was performed weekly, for
ix months post-transplant. Sixteen patients were found to
e positive for pp65 antigenemia, with a similar incidence
etween groups (Table 3). The time-line occurrence in weeks
f positive cases is depicted in Fig. 1. There were no posi-
ive results in the ﬁrst three weeks of monitoring and the
requency of positivity peaked on week eight. Six month
ost-transplant only one patient relapsed after three nega-
ive evaluations. When comparing the positivity rate along the
eeks between the study groups (Fig. 2), there was a trend for
 higher and earlier frequency of positivity among those on
niversal prophylaxis than in those on preemptive therapy.
n addition, the positivity tended to last longer in the univer-
al prophylaxis group (4.11 ± 1.83 weeks vs. 2.71 ± 0.95 weeks,
 = 0.090).
From the nine positive patients on universal prophy-
axis (mean age of 46.2 ± 9.2 years), three were male. All of
hem had gastrointestinal manifestations, and in three the
irus was also identiﬁed by immunohistochemistry in kid-
ey biopsies. One patient was considered clinically resistant
o ganciclovir by clinicians and managed with immunoglob-
lin. Hemophagocytic lymphohistiocytosis was diagnosed in
ne case. Two of positive cases had a severe form of the disease
ith a fatal course. From the seven positive patients on pre-
mptive therapy (mean age 51.4 ± 10.5 years), ﬁve were male.Please cite this article in press as: Carvalho FR, et al. Clinical correlates 
transplant in patients undergoing universal prophylaxis or preemptive ther
ere, every positive patient remained asymptomatic.
The mean number of cells of the positive patients and the
erological response to HCMV infection are shown in Fig. 3.
 signiﬁcant difference in the number of positive cells/2 × 105 when comparing universal prophylaxis versus preemptive therapy.
leukocytes between groups in favor of universal prophylaxis
was found (123 ± 423 vs. 23 ± 87, p < 0.01). No difference was
observed between groups regarding serum levels of either IgG
or IgM anti-HCMV.
Discussion
HCMV infection is a major concern in kidney transplantation
especially during the ﬁrst three months of post-transplant
when higher doses of immunosuppressant are required.15 The
proﬁle of both pp65 antigenemia and serological studies were
evaluated under universal prophylaxis or preemptive therapy,
and the clinical courses of the two groups were compared.
The positivity of pp65 antigenemia test can precede clinicalof pp65 antigenemia monitoring in the ﬁrst months of post kidney
apy. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.09.016
Fig. 1 – Positivity rate for antigenemia pp65 assay
(cut-off > 10 positive cells/2 × 105 leukocytes) in kidney
transplant patients along the study period.
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Table 2 – Baseline characteristics of recipients, according to the strategy adopted for managing HCMV post kidney
transplantation.
Receptor parameters All Universal prophylaxis Preemptive therapy
N 32 18 14
Age (y) 47  ± 9 46  ± 8 49  ± 9
Male gender, f (%) 14  (44%) 5 (28%) 9  (64%)
Skin color, f (%)
White 16 (50%) 11 (61%) 5 (36%)
Non-White 16 (50%) 7 (39%) 9 (64%)
Time on dialysis (y) 4.2 ± 2.4 4.7 ± 2.8 3.8 ± 1.9
Retransplantation, f (%) 3 (9%) 2 (11%) 1 (7%)
Transfusion, f (%) 10 (31%) 7 (39%) 3 (21%)
Primary renal disease, f (%)
Hypertension 9 (28%) 6 (33%) 3 (21%)
Diabetes 4 (13%) 4 (22%) –
Glomerulonephritis 3 (9%) 1 (6%) 2 (14%)
ADPKD 8 (25%) 2 (11%) 6 (43%)
SLE 1 (3%) 1 (6%) –
Other 1 (3%) 1 (6%) –
Undetermined 6 (19%) 3 (17%) 3 (21%)
HLA A/B mismatches 3.1 ± 0.9 3.5 ± 0.5 2.6 ± 1.0
HLA DR mismatches 0.8 ± 0.7 0.8 ± 0.8 0.9 ± 0.6
PRA I
Negative, f (%) 24 (75%) 11 (61%) 13 (93%)
<50% 5 (16%) 4 (22%) 1 (7%)
>50% 3 (9%) 3 (17%) –
PRA II
Negative, f (%) 26 (81%) 13(72%) 13 (93%)
<50% 5 (16%) 4 (22%) 1 (7%)
>50% 1 (3%) 1  (100%) –
HCMV serologic status, f (%)
Positive 28 (88%) 16 (89%) 12 (86%)
Negative 4 (13%) 2 (11%) 2 (14%)
ntigen; PRA, panel reactive antibody. Again, no statistically signiﬁcant was
xis versus preemptive therapy.
50
40
30
t o
f p
p6
5 
po
sit
ive
 p
at
ie
nt
s
20Mean ± SD. HCMV, human cytomegalovirus; HLA, human leukocyte a
found for any of the parameters when comparing universal prophyla
The mean age of the donors was similar to other
studies,18,19 and the positivity rate of IgG anti-HCMV was
100%. More  importantly, the analyzed parameters did not dif-
fer between groups. The mean age of recipients was also in
the range reported by most of the studies.20–22 The proﬁle
of the underlying disease was comparable to that described
by the Brazilian census of dialysis but with a high percent
of ADPKD patients.23 As expected, the proportion of sensi-
tized patients tended to be higher in the universal prophylaxis
group.Please cite this article in press as: Carvalho FR, et al. Clinical correlates of pp65 antigenemia monitoring in the ﬁrst months of post kidney
transplant in patients undergoing universal prophylaxis or preemptive therapy. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.09.016
Consistent with the reported frequency of HCMV infection
in the renal transplant population (30–70%),24,25 the over-
all frequency of HCMV infection in our sample was 50%.
Table 3 – Frequency of positive and negative cases for
pp65 antigenemia in preemptive therapy and universal
prophylaxis after kidney transplantation.
Group pp65+ pp65− All
Universal prophylaxis 9 9 18
Preemptive therapy 7 7 14
Total 16 16 32
Pe
rc
e
n
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0
0 1 2 3 4 5 6 7 8
Weeks post-transplant
9 10 11 12 24
Fig. 2 – Positivity rate for pp65 antigenemia assay in kidney
transplant patients followed for six months, stratiﬁed by
the type of strategy adopted (black columns represent the
universal prophylaxis group and gray columns the
preemptive therapy group).
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Fig. 3 – Comparison between viral replication proﬁle of
HCMV by pp65 antigenemia assay (dashed line) and IgM
and IgG levels (gray and black columns, respectively) during
the study period in kidney transplant patients on universal
p
U
l
w
p
p
I
a
p
b
o
e
A
o
g
a
c
a
h
p
l
s
trophylaxis (Panel A) or preemptive therapy (Panel B).
nexpectedly, the rate of HCMV infection in universal prophy-
axis and preemptive therapy was the same.
The ﬁrst positive patient for pp65 antigenemia in our study
as detected at week 4, in line with previous reports.16,26 The
eak of affected patients occurred at week 8. In some way sur-
rising, the ﬁrst positive patient was on universal prophylaxis.
ndeed, the positivity rate was higher in the ﬁrst weeks as well
s in the last weeks of the study in the group on universal pro-
hylaxis compared to those on preemptive therapy. It should
e pointed out that HCMV infection was more  severe in those
n universal prophylaxis resulting in two fatalities. In the pre-
mptive therapy group, none of the patient had symptoms.
ccordingly, the number of infected cells and the duration
f positivity were both higher in the universal prophylaxis
roup. Interestingly, despite the differences in clinical picture
nd in the initial immunosuppressant schedule, the serologi-
al response, as evaluated by the serum levels of speciﬁc IgG
nd IgM, was similar in both groups.
There is almost a consensus in the literature regarding a
igher incidence of HCMV following the end of the universal
rophylaxis period.27,28 In view of that the period of prophy-Please cite this article in press as: Carvalho FR, et al. Clinical correlates 
transplant in patients undergoing universal prophylaxis or preemptive ther
axis initially recommended as three months was extended to
ix months.9 However, if universal prophylaxis is more  effec-
ive than preemptive therapy in terms of the prevention of;x  x x(x x):xxx–xxx 5
the infection and its morbidity is a matter of controversy. The
use of different drugs, protocols and routes of administration
for universal prophylaxis with potential different results may
add some fuel to the debate. In a recent meta-analysis, gan-
ciclovir was found to be comparable to either valganciclovir
or valacyclovir regarding the prevention of CMV  disease.28 In
the present study, universal prophylaxis, when implemented
with intravenous ganciclovir, was found to be inferior to pre-
emptive therapy: the rate of HCMV infection was not reduced
and the morbidity of the infection was substantially higher
with universal prophylaxis. The explanation for the partic-
ularities of the clinical course of HCMV infection under the
two management strategies is uncertain but two  possibili-
ties could be proposed. Patients under universal prophylaxis
underwent more  aggressive immunosuppression, which may
have impaired their immune response against HCMV. In addi-
tion, the use of suboptimal doses of intravenous ganciclovir
may have perturbed the process of leukocyte invasion by the
virus. As a result, an underlying HCMV infection could remain
unrevealed and the diagnosis would only be made in a rela-
tively advanced stage of the disease. In this circumstance, the
use of more  than 10 cells as a cutoff could be inappropriate.
We wonder if adopting 1 cell/2 × 105 leukocytes as a cutoff for
a positive test, as already recommended in other solid organ
transplantation,7,29 would have changed the course of disease
of those on universal prophylaxis.
Reports using intravenous ganciclovir as universal prophy-
laxis are scarce in the literature since oral administration of
drugs is the preferred route in this setting. However, consistent
with our ﬁndings, a study with intravenous ganciclovir as uni-
versal therapy in lung transplantation reported a rate of 68%
of HCMV infection in the ﬁrst year post-transplant.30 Perhaps
not accidently, the study was also carried out in our country, in
which oral drugs for HCMV prophylaxis are not made available
by the public health system. Considering the mentioned speci-
ﬁcity of the present study, our ﬁndings cannot be used to argue
the concept that universal prophylaxis with oral drugs reduces
and delays HCMV infection.18,21,31 It does suggest though that
when implemented using intravenous ganciclovir, universal
prophylaxis does not seem to be warranted in light of our
ﬁndings.
In conclusion, the present study reiterate that routine mon-
itoring during the ﬁrst three post-transplant months has a
positive impact on early detection of HCMV replication allow-
ing timely treatment to reduce the morbidity of the disease.
The strategy of universal therapy employing intravenous gan-
ciclovir was associated to a more  severe clinical course of
HCMV infection allowing us to think that the use of >10
cells/2 × 105 leukocytes as a cutoff in this setting may be inap-
propriate. Further studies, with larger sample sizes, may be
needed to conﬁrm our results.
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